SpectRx divests SimpleChoice
This article was originally published in The Gray Sheet
Executive Summary
Firm sells insulin pump infusion set business to ICU Medical for undisclosed terms May 9. The move is part of SpectRx's plan to refocus on its noninvasive LightTouch cervical cancer detection business (1"The Gray Sheet" March 19, 2007, In Brief). ICU Medical introduced its own Orbit 90 diabetes infusion set in 2006...
You may also be interested in...
SpectRx seeks buyer for insulin pump infusion set unit
Firm's SimpleChoice insulin pump infusion set business is up for sale as part of a broader SpectRx reorganization aimed at refocusing the company on its noninvasive LightTouch cervical cancer detection technology, including funding ongoing pivotal trials of the device, the firm says March 15. SpectRx also is seeking a partner for its development-stage continuous glucose monitoring technology. LightTouch, which uses light to scan the cervix for disease, is intended as a triage step for women with positive Pap smear or human papillomavirus (HPV) tests to confirm whether colposcopy and biopsy are warranted (1"The Gray Sheet" Sept. 18, 2006, In Brief)...
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.